PTPIOTCPharmaceutical PreparationsFiscal year ends December 31
Petros Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.00+0.00 (+5.56%)
Close on Oct 19, 2026
- Market cap
- $135.07K
- P/E (TTM)
- –
- Dividend yield
- –
Petros Pharmaceuticals, Inc. revenue by segment
By business segment
| Revenue | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q2 21 | TTM Q1 21 | TTM Q4 20 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Devices | $3.15M | $3.07M | $3.10M | $3.30M | $3.54M | $3.55M | $3.48M | $3.33M | $3.26M | $3.26M | $3.08M | $3.20M | 100.0% | -10.9% |
| Prescription Medications | – | – | – | – | – | $3.43M | $368.39K | $2.72M | $2.73M | $9.67M | $8.76M | $6.36M | – | – |
By product or service
By region
| Revenue | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q2 21 | TTM Q1 21 | TTM Q4 20 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $4.04M | – | – | – | – | $5.79M | $2.65M | $4.91M | $4.80M | $11.79M | $10.81M | $8.56M | 79.1% | – |
| International | $1.07M | $1.07M | $1.07M | $1.15M | $1.30M | $1.19M | $1.20M | $1.13M | $1.19M | $1.13M | $1.03M | $1.00M | 20.9% | -17.5% |
From the segment and revenue-disaggregation notes of Petros Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.